You are here:

infliximab (Remicade)

Advice

following a full submission:

infliximab (Remicade®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies

SMC restriction: as an alternative to ciclosporin in patients with acute, severe paediatric ulcerative colitis (rescue therapy) who are steroid refractory.

Open-label, uncontrolled data indicate that infliximab induces remission of moderate to severe active ulcerative colitis in paediatric patients.

Drug Details

Drug Name: infliximab (Remicade)
SMC Drug ID: 854/13
Manufacturer: MSD
Indication: treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
BNF Category:
Sub Category: 10.1 Drugs used in rheumatic diseases and gout
Submission Type: Full submission
Status: Superseded
Date Advice Published: 11 March 2013

Back